Bimzelx

Active Ingredient(s): Bimekizumab-bkzx
FDA Approved: * October 17, 2023
Pharm Company: * UCB INC
Category: Arthritis
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Bimzelx 160 mg/ml Subcutaneous Injection, Solution
NDC: 50474-780
Labeler:
Ucb, Inc.
Bimzelx 160 mg/ml Subcutaneous Injection, Solution
NDC: 50474-781
Labeler:
Ucb, Inc.